152 related articles for article (PubMed ID: 1564524)
1. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Rupniak NM; Tye SJ; Brazell C; Heald A; Iversen SD; Pagella PG
J Neurol Sci; 1992 Feb; 107(2):246-9. PubMed ID: 1564524
[TBL] [Abstract][Full Text] [Related]
2. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Neurosci Lett; 1992 Sep; 144(1-2):79-83. PubMed ID: 1436716
[TBL] [Abstract][Full Text] [Related]
3. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
4. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.
Dawson GR; Bentley G; Draper F; Rycroft W; Iversen SD; Pagella PG
Pharmacol Biochem Behav; 1991 Aug; 39(4):865-71. PubMed ID: 1763105
[TBL] [Abstract][Full Text] [Related]
5. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Psychopharmacology (Berl); 1993; 112(4):415-20. PubMed ID: 7871051
[TBL] [Abstract][Full Text] [Related]
6. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Braida D; Sala M
CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
[TBL] [Abstract][Full Text] [Related]
7. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys.
Rupniak NM; Tye SJ; Field MJ
Psychopharmacology (Berl); 1997 Jun; 131(4):406-10. PubMed ID: 9226744
[TBL] [Abstract][Full Text] [Related]
8. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
Matsuoka N; Aigner TG
J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models.
Rupniak NM; Field MJ; Samson NA; Steventon MJ; Iversen SD
Neurobiol Aging; 1990; 11(6):609-13. PubMed ID: 2280804
[TBL] [Abstract][Full Text] [Related]
10. Effects of cholinergic drugs on scopolamine-induced memory impairment in rhesus monkeys.
Hironaka N; Ando K
Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Jun; 16(3):103-8. PubMed ID: 8905798
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the decarbamoylation rates of physostigmine-inhibited plasma and red cell cholinesterases of man with other species.
Wetherell JR; French MC
Biochem Pharmacol; 1991 Jul; 42(3):515-20. PubMed ID: 1907148
[TBL] [Abstract][Full Text] [Related]
12. Evidence against a specific effect of cholinergic drugs on spatial memory in primates.
Rupniak NM; Samson NA; Tye SJ; Field MJ; Iversen SD
Behav Brain Res; 1991 Apr; 43(1):1-6. PubMed ID: 1859616
[TBL] [Abstract][Full Text] [Related]
13. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
Shannon HE; Bemis KG; Hendrix JC; Ward JS
J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.
Rupniak NM; Steventon MJ; Field MJ; Jennings CA; Iversen SD
Psychopharmacology (Berl); 1989; 99(2):189-95. PubMed ID: 2508153
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.
al-Jafari AA; Kamal MA; Greig NH; Alhomida AS; Perry ER
Biochem Biophys Res Commun; 1998 Jul; 248(1):180-5. PubMed ID: 9675107
[TBL] [Abstract][Full Text] [Related]
16. Physostigmine-induced hypothermic response in rats and its relationship with endogenous arginine vasopressin.
Yang YL; Shen ZL; Zou Q; Tang Y; Huang T
Life Sci; 2009 Oct; 85(15-16):586-91. PubMed ID: 19723529
[TBL] [Abstract][Full Text] [Related]
17. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
Utsuki T; Uchimura N; Irikura M; Moriuchi H; Holloway HW; Yu QS; Spangler EL; Mamczarz J; Ingram DK; Irie T; Greig NH
J Pharmacol Exp Ther; 2007 Apr; 321(1):353-61. PubMed ID: 17255466
[TBL] [Abstract][Full Text] [Related]
18. Possible interaction of cholinergic and GABAergic systems between MS and CA1 upon memory acquisition in rats.
Yousefi B; Nasehi M; Khakpai F; Zarrindast MR
Behav Brain Res; 2012 Dec; 235(2):231-43. PubMed ID: 22909986
[TBL] [Abstract][Full Text] [Related]
19. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Braida D; Paladini E; Griffini P; Lamperti M; Maggi A; Sala M
Eur J Pharmacol; 1996 Apr; 302(1-3):13-20. PubMed ID: 8790986
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
